54P Impact of treatment sequence between immune checkpoint inhibitors and paclitaxel/cetuximab in recurrent or metastatic head and neck cancer

ESMO rare cancers. 2026 Open access

Read full text
Authors: E. Toda, Jumpei Yoshida, Naoki Fukuda, K. Nakano, X. Wang, R. Oki, Takehiro Nakao, T. Urasaki, Junichi Tomomatsu, S. Takahashi, Yuji Miura
DOI: 10.1016/j.esmorc.2026.100260
Cited by: 0

Abstract

Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Previous studies suggest that ICIs may enhance not only first-line outcomes but also the effectiveness of subsequent therapies; however, the heterogeneity of post-ICI treatments has not been adequately evaluated. Thus, it remains unclear whether prior ICI exposure truly influences the efficacy of subsequent chemotherapy. This study aimed to assess whether prior ICI exposure improves the outcomes of paclitaxel plus cetuximab (PC).

Fields of Study & Subjects

Head and Neck Cancer Studies Cancer Immunotherapy and Biomarkers Nonmelanoma Skin Cancer Studies

Publication details

Journal / source
ESMO rare cancers.
Volume
5
Pages
100260–100260
Publication date
1 March 2026
Language
EN